Clinical · Molecular biology
Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors
Summary
This retrospective single-center study investigated the role of TERT promoter mutations as a biomarker to guide treatment in advanced melanoma, particularly in BRAF V600 mutant patients. TERT mutations were detected in 73% of 159 patients and frequently co-occurred with BRAF V600 mutations. While TERT status was not an independent prognostic factor, exploratory analyses suggested a potential interaction with treatment type. Patients with BRAF/TERT co-mutations showed longer overall survival when treated with immune checkpoint inhibitors, whereas the opposite trend was observed for TERT wild-type patients receiving BRAF/MEK inhibitors. These preliminary findings warrant further validation in prospective studies.
Critical appraisal
Clinical. This retrospective phase II/III study explores a potential predictive biomarker, TERT promoter mutations, to optimize therapeutic selection in patients with advanced BRAF V600-mutant melanoma. Exploratory results suggest that patients with BRAF/TERT co-mutations might benefit more from ICIs (OS 50.3 months) than from BRAF/MEK inhibitors (OS 14.6 months), while the opposite trend is observed for TERT wild-type patients (OS 7.8 months with ICIs vs 20.9 months with BRAF/MEK inhibitors). However, these data are from small subgroups and not consistently supported by multivariable analyses, limiting their immediate clinical impact. A well-designed prospective study would be justified to validate these observations and could potentially change clinical practice within 3 to 5 years if confirmed.
Molecular biology. TERT mutational status and co-mutations were assessed using a customized next-generation sequencing (NGS) panel, a robust technology for variant identification. The study revealed a high frequency of TERT mutations (73%) and strong co-occurrence with BRAF V600 mutations (84%) in metastatic melanoma. While the underlying biological mechanism for the observed interaction between TERT status and treatment response remains to be elucidated, these findings open avenues for understanding melanoma biology and resistance/sensitivity to targeted therapies and immunotherapy. Validation of TERT as a predictive biomarker could lead to the development of companion clinical tests.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology